We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Fernando Bril MD

Fernando Bril MD

Assistant Professor, Division of Endocrinology, Diabetes and Metabolism, Division of Internal Medicine, Department of Medicine, University of Florida, Gainesville, Florida

Even before starting his Internal Medicine residency, Dr. Bril had a strong interest in clinical research and biostatistics, embarking early-on on a career as a physician-scientist. He joined the Division of Endocrinology, Diabetes and Metabolism at the University of Florida in Gainesville, Florida, in 2012 as a Post-Doctoral Associate. Later, Dr. Bril stayed as a faculty member, first as an Assistant Scientist, and subsequently as an Assistant Professor.

Dr. Bril’s main research interest has been to understand the metabolic mechanisms that promote the progression from isolated steatosis to NASH and to identify pharmacological approaches that could be used to delay this progression. His research group has carried out several clinical and translational research studies that have resulted in significant peer-reviewed articles in the field, including 2 randomized controlled trials on the use of pioglitazone alone or combined with vitamin E (Cusi, et al. Annals Intern Med 2016; Bril, et al Diabetes Care 2019). More specifically, in the last few years, they have carefully examined how the severity of liver disease influences changes in dyslipidemia, diabetes control, and insulin resistance, all mechanisms potentially leading to this increased cardiovascular risk in patients with NAFLD (Bril, et al. Hepatology 2017; Bril, et al J Clin Endocrinol Metab 2016; Bril, et al. Hepatology 2014). Dr. Bril and his research group have also focused on the assessment of potential new plasma and imaging biomarkers for the diagnosis of NAFLD (Bril, et al. Diabetes Care 2019; Bril, et al. Diabetes Obes Metab 2018; Bril, et al. Liver Int 2015; Bril, et al J Hepatol 2015).



Dr. Bril has nothing to disclose.

Recent Contributions to PracticeUpdate:

  1. Increased Risk of NAFLD in Women With Gestational Diabetes